Kura Oncology (NASDAQ:KURA) Downgraded to Hold at Zacks Investment Research
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
A number of other brokerages have also weighed in on KURA. ValuEngine raised shares of United Overseas Bank from a sell rating to a hold rating in a report on Monday, June 17th. Leerink Swann set a $27.00 price target on shares of Kura Oncology and gave the company a buy rating in a report on Saturday, June 15th. HC Wainwright set a $31.00 price target on shares of Kura Oncology and gave the company a buy rating in a report on Wednesday, May 8th. Wedbush started coverage on shares of Pinterest in a report on Monday, June 17th. They issued an outperform rating and a $33.00 price target for the company. Finally, Citigroup set a $27.00 price target on shares of PhaseBio Pharmaceuticals and gave the company a buy rating in a report on Friday, May 24th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $28.00.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.08. Equities research analysts expect that Kura Oncology will post -1.71 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. CWM LLC acquired a new stake in Kura Oncology during the 1st quarter worth $25,000. Great West Life Assurance Co. Can acquired a new stake in Kura Oncology during the 4th quarter worth $62,000. Legacy Advisors LLC acquired a new stake in Kura Oncology during the 1st quarter worth $65,000. Legal & General Group Plc grew its holdings in Kura Oncology by 21.7% during the 4th quarter. Legal & General Group Plc now owns 5,175 shares of the company’s stock worth $73,000 after acquiring an additional 923 shares during the period. Finally, BNP Paribas Arbitrage SA grew its holdings in Kura Oncology by 293,950.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 5,881 shares of the company’s stock worth $98,000 after acquiring an additional 5,879 shares during the period. 83.93% of the stock is owned by hedge funds and other institutional investors.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
See Also: What is the market perform rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.